-
Sinovent Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
•
Sinovent Inc., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital,…
-
Sinovent Enrolls First Patient in Phase III Trial for Gout Drug XNW3009
•
Suzhou-based Sinovent Inc. has announced the enrollment of its first patient in a Phase III clinical study for XNW3009, a novel gout drug candidate designed to inhibit the human urate transporter 1 (URAT1) and address gout-related hyperuricemia. Founded in 2016, Sinovent operates across multiple locations, including Beijing, Shanghai, Australia, and…
